ReEmerge

ReEmerge operates at the intersection of medical devices, therapeutics, rehabilitation, and neurotechnology. Its stated focus is chronic cognitive impairment after traumatic brain injury, with Cognitive Network Restoration Therapy (CNRT) designed to stimulate underactive but viable neural circuits. That emphasis on restoring function in existing networks distinguishes its stated approach from care framed primarily around compensating for deficits, although clinical evidence and comparative outcomes are not detailed here. The company is at an early stage: founded in 2023, privately held, and reporting one $37 million Series A in September 2026. Its seven-investor syndicate includes Sante Ventures and U.S. Venture Partners as leads, alongside Oxford Science Enterprises and other firms. The available profile does not identify named direct competitors or provide comparative product, regulatory, or clinical data, so a specific company-to-company ranking would be premature. ReEmerge should instead be viewed within the broader neurorehabilitation and neurostimulation landscape, where differentiation will depend on evidence of safety, efficacy, treatment durability, and a practical path to clinical adoption. CNRT remains investigational and is not approved for commercial use.

ReEmerge’s growth profile has a clear financing and commercialization inflection point in September 2026. Founded in 2023, the company emerged from stealth with a $37 million Series A announced on Sep 15, 2026 and a launch announcement the following day. The round is its only listed financing and brings reported total funding to $37 million; Sante Ventures and U.S. Venture Partners led a seven-investor syndicate. This capital coincides with the company’s public introduction of Cognitive Network Restoration Therapy, an investigational neurostimulation approach for persistent cognitive impairment following traumatic brain injury. Leadership changes also precede the launch: Jonathan Baker’s board role began in February 2026, and Todd Langevin became CEO in May 2026. These milestones suggest a transition from company formation and stealth toward developing and advancing the therapy, but public details on clinical milestones, product availability, hiring plans, and employee growth are limited. The therapy is not approved for commercial use, and no additional funding rounds or product launches are listed. Its next indicators of progress will be clinical evidence, regulatory development, and execution against the stated restoration-focused treatment approach.